Skip to main content
. 2020 Jul 9;10(19):8468–8478. doi: 10.7150/thno.46241

Figure 3.

Figure 3

The effects of serum piR-54265 in CRC clinic surveillance and comparison with other currently used cancer biomarkers. A, Serum levels of piR-54265, CEA, CA19-9 and CA125 in 46 patients with CRC before and after surgical resection. P for Mann-Whitney U-test. B, Continual decline of serum piR-54265 levels in 3 patients after different days of surgical removal of CRC. P of Student's t-test for the average levels before and after surgery. C, Serum levels of piR-54265, CEA, CA19-9 and CA125 in 3 CRC patients before and after surgery and the time tumor relapse was diagnosed. P for Student's t-test; n.s., not significant. D, Serum piR-54265 levels in 3 CRC patients before surgery, 7 days after surgery, and at the time when tumor relapses as indicated by the arrows. P for Student's t-test. E, Plasma methylated-SEPTIN9 changes in 46 patients before and after surgical removal of CRC. The dot lines in A-D indicate the cut-off values of each marker (piR-54265, 1500 copies/µL; CEA, 5 ng/mL; CA19-9, 35 unit/mL and CA125, 35 unit/mL).